美康生物（300439）2025年三季报简析：净利润同比下降73.02%，公司应收账款体量较大

中金财经2025-10-30

据证券之星公开数据整理，近期美康生物(300439)发布2025年三季报。截至本报告期末，公司营业总收入11.36亿元，同比下降19.27%，归母净利润6053.38万元，同比下降73.02%。按单季度数据看，第三季度营业总收入3.99亿元，同比下降12.71%，第三季度归母净利润370.01万元，同比下降91.94%。本报告期美康生物公司应收账款体量较大，当期应收账款占最新年报归母净利润比达...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2579783156?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/ http://caiji.3g.cnfol.com/colect/202510/30/20251030587688.png?op=imageView2&mode=2&width=256&height=256&quality=70&format=png","is_english":false,"pubTime":"2025-10-30 08:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579783156","market":"hk","top_or_hot":-1,"title":"美康生物（300439）2025年三季报简析：净利润同比下降73.02%，公司应收账款体量较大","media":"中金财经","content":"<div>\n<p>据证券之星公开数据整理，近期美康生物(300439)发布2025年三季报。截至本报告期末，公司营业总收入11.36亿元，同比下降19.27%，归母净利润6053.38万元，同比下降73.02%。按单季度数据看，第三季度营业总收入3.99亿元，同比下降12.71%，第三季度归母净利润370.01万元，同比下降91.94%。本报告期美康生物公司应收账款体量较大，当期应收账款占最新年报归母净利润比达...</p>\n\n<a href=\"http://sc.stock.cnfol.com/gushiyaowen/20251030/31748828.shtml\">网页链接</a>\n\n</div>\n","source":"zhongjincaijing_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美康生物（300439）2025年三季报简析：净利润同比下降73.02%，公司应收账款体量较大</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美康生物（300439）2025年三季报简析：净利润同比下降73.02%，公司应收账款体量较大\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-30 08:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://sc.stock.cnfol.com/gushiyaowen/20251030/31748828.shtml><strong>中金财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>据证券之星公开数据整理，近期美康生物(300439)发布2025年三季报。截至本报告期末，公司营业总收入11.36亿元，同比下降19.27%，归母净利润6053.38万元，同比下降73.02%。按单季度数据看，第三季度营业总收入3.99亿元，同比下降12.71%，第三季度归母净利润370.01万元，同比下降91.94%。本报告期美康生物公司应收账款体量较大，当期应收账款占最新年报归母净利润比达...</p>\n\n<a href=\"http://sc.stock.cnfol.com/gushiyaowen/20251030/31748828.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300439","symbol_name":"美康生物","start_time":0,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251030/31748828.shtml","article_id":"2579783156","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/ http://caiji.3g.cnfol.com/colect/202510/30/20251030587688.png?op=imageView2&mode=2&width=256&height=256&quality=70&format=png"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579783156","pubTimestamp":1761782762,"columns":[],"sourceInfo":{"source_id":"zhongjincaijing_highlight","name":"中金在线"},"weMediaInfo":null,"summary":"据证券之星公开数据整理，近期美康生物发布2025年三季报。截至本报告期末，公司营业总收入11.36亿元，同比下降19.27%，归母净利润6053.38万元，同比下降73.02%。按单季度数据看，第三季度营业总收入3.99亿元，同比下降12.71%，第三季度归母净利润370.01万元，同比下降91.94%。本报告期美康生物公司应收账款体量较大，当期应收账款占最新年报归母净利润比达222.79%。去年的净利率为15.08%，算上全部成本后，公司产品或服务的附加值高。","collect":0,"end_time":0,"defaultTopTitle":"cnfol.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"300439":"美康生物"},"translate_title":"Brief analysis of the third quarterly report of Meikang Biotech (300439) in 2025: Net profit fell by 73.02% year-on-year, and the company's accounts receivable are relatively large","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300439":1.5},"content_text":"据证券之星公开数据整理，近期美康生物(300439)发布2025年三季报。截至本报告期末，公司营业总收入11.36亿元，同比下降19.27%，归母净利润6053.38万元，同比下降73.02%。按单季度数据看，第三季度营业总收入3.99亿元，同比下降12.71%，第三季度归母净利润370.01万元，同比下降91.94%。本报告期美康生物公司应收账款体量较大，当期应收账款占最新年报归母净利润比达222.79%。本次财报公布的各项数据指标表现不尽如人意。其中，毛利率39.64%，同比减13.06%，净利率5.19%，同比减67.34%，销售费用、管理费用、财务费用总计3.03亿元，三费占营收比26.7%，同比增25.93%，每股净资产7.69元，同比增2.22%，每股经营性现金流0.38元，同比增32.83%，每股收益0.16元，同比减73.03%    证券之星价投圈财报分析工具显示：业务评价：公司去年的ROIC为8.76%，资本回报率一般。去年的净利率为15.08%，算上全部成本后，公司产品或服务的附加值高。从历史年报数据统计来看，公司上市以来中位数ROIC为12.07%，投资回报也较好，其中最惨年份2019年的ROIC为-14.64%，投资回报极差。公司历史上的财报相对一般(注：公司上市时间不满10年，上市时间越长财务均分参考意义越大。)，公司上市来已有年报9份，亏损年份1次，需要仔细研究下有无特殊原因。商业模式：公司业绩主要依靠营销驱动。需要仔细研究这类驱动力背后的实际情况。财报体检工具显示：建议关注公司应收账款状况(应收账款/利润已达222.79%)为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579783156","isCrawlerRequest":true}